Skip to main content

Table 1 Detailed information of the included head and neck cancer patients

From: Automatic interactive optimization for volumetric modulated arc therapy planning

Patient number

Disease site

Stage

PTV E (cm 3 )

PTV T (cm 3 )

PTV B (cm 3 )

Comp sal * (cm 3 )

Comp swal (cm 3 )

Oral cavity (cm 3 )

1

Larynx

T2N2c

428.7

93.7

243.3

66.7

7.1

-

2

Oropharynx

T2N2b

441.7

48.3

188.6

82.3

16.5

-

3

Oropharynx

T2N2a

240.6

43.4

94.5

42.4

25.0

-

4

Oropharynx

T4N1

288.2

57.3

237.5

60.6

10.6

-

5

Oropharynx

T4aN1

280.8

79.5

164.5

78.9

32.0

36.7

6

Oropharynx

T4aN2b

288.2

57.3

237.5

60.6

10.6

14.6

7

Oropharynx

T4aN1

360.4

62.9

143.7

73.0

35.0

57.1

8

Oropharynx

T3N1

500.3

87.9

231.7

55.0

11.9

29.4

9

Oropharynx

T4aN2c

258.4

155.7

328.9

38.3

4.8

38.1

10

Hypopharynx

T2N3

264.0

137.0

607.0

70.8

10.3

60.6

  1. The disease site, stage and volumes of the elective, transition and boost planning target volumes (PTVE, PTVT, PTVB respectively) and the volumes of the composite salivary and swallowing structures for all patients. The oral cavity was included as an organ-at-risk in 6/10 patients.
  2. Abbreviations:
  3. *Compsal = Composite salivary glands. Depending on degree of overlap with the PTVs and choice for inclusion by the treating clinician, compsal could consist of some, or all, of the ipsilateral and contralateral parotid and submandibular glands.
  4. Compswal = Composite swallowing muscles. Could consistent of some, or all, of the upper esophageal sphincter, upper and lower parts of the larynx, the superior, medial and inferior pharyngeal constrictor muscle, the cricopharyngeal muscle and the esophagus.